Oberfeld Blake, Golsoorat Pahlaviani Fatemeh, El Helwe Hani, Falah Henisk, Hall Nathan, Trzcinski Jonathan, Solá-Del Valle David
Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, MA, USA.
University of Florida, Department of Ophthalmology, Gainesville, FL, USA.
Clin Ophthalmol. 2024 Jul 19;18:2125-2136. doi: 10.2147/OPTH.S465828. eCollection 2024.
Despite holding promise, reports of using MIGS in severe glaucoma are scarce, and none has described combining multiple MIGS in this population. To the best of our knowledge, this is the largest study to report outcomes of phacoemulsification and MIGS (Phaco/MIGS) in patients with severe glaucoma.
This retrospective review comprised 327 clinical visits of 71 patients with severe glaucoma who underwent Phaco/MIGS with iStent, endocyclodestruction, Kahook Dual Blade, Hydrus Microstent, or a combination of these MIGS (cMIGS) performed between 2016 and 2021. Primary outcomes included intraocular pressure (IOP) and medication burden evaluated by Generalized Estimating Equations, as well as Kaplan-Meier Estimates. Further analyses compared the efficacy of cMIGS and single Phaco/MIGS (sMIGS), procedure duration, visual acuity, and complications.
Mean preoperative IOP was 16.7 mmHg ± 5.8 (SD) on 2.3 ± 1.9 medications overall (N = 71), 16.9 ± 6.3 mmHg on 1.7 ± 1.9 medications in the sMIGS group (N = 37), and 16.4 ± 5.3 mmHg on 2.9 ± 1.6 medications in the cMIGS group (N = 34). Throughout 12 months, Phaco/MIGS led to significant reduction patterns in IOP (p < 0.001) and medications (p = 0.03). At 12 months, 47.5%, 87.5%, and 64.7% of the patients achieved IOP ≤ 12 mmHg, 17 mmHg, or predetermined goal IOP, respectively, without additional medication or procedure. Mean 12-month IOP was 13.5 ± 3.1 mmHg on 1.8 ± 1.7 medications. After adjusting for baseline medication burden, the reduction pattern in IOP (p < 0.05) was different between cMIGS and sMIGS, favoring cMIGS, and the groups had similar reduction patterns in medications (p = 0.75).
The use of Phaco/MIGS in patients with cataract and severe glaucoma may significantly reduce IOP and medication burden throughout 12 months and, thus, may serve as a stepping stone in severe glaucoma patients with visually significant cataract before proceeding with more invasive glaucoma surgery. This effect may be potentiated by the combination effect of cMIGS.
尽管有前景,但关于在严重青光眼患者中使用微侵袭性青光眼手术(MIGS)的报道很少,且没有研究描述在该人群中联合使用多种MIGS的情况。据我们所知,这是报告白内障超声乳化联合MIGS(Phaco/MIGS)治疗严重青光眼患者疗效的最大规模研究。
本回顾性研究纳入了2016年至2021年间接受Phaco/MIGS手术的71例严重青光眼患者的327次临床就诊记录,手术方式包括使用iStent、睫状体破坏术、Kahook双刃刀、Hydrus微支架或这些MIGS的联合使用(cMIGS)。主要结局包括通过广义估计方程评估的眼压(IOP)和药物负担,以及Kaplan-Meier估计值。进一步分析比较了cMIGS和单一Phaco/MIGS(sMIGS)的疗效、手术持续时间、视力和并发症。
总体上(N = 71),术前平均IOP为16.7 mmHg ± 5.8(标准差),使用2.3 ± 1.9种药物;sMIGS组(N = 37)术前平均IOP为16.9 ± 6.3 mmHg,使用1.7 ± 1.9种药物;cMIGS组(N = 34)术前平均IOP为16.4 ± 5.3 mmHg,使用2.9 ± 1.6种药物。在12个月的随访期间,Phaco/MIGS使IOP(p < 0.001)和药物使用量(p = 0.03)显著降低。在12个月时,分别有47.5%、87.5%和64.7%的患者在未进行额外药物治疗或手术的情况下,IOP≤12 mmHg、≤17 mmHg或达到预定目标IOP。12个月时的平均IOP为13.5 ± 3.1 mmHg,使用1.8 ± 1.7种药物。在调整基线药物负担后,cMIGS和sMIGS在IOP降低模式上存在差异(p < 0.05),cMIGS更具优势,而两组在药物使用量降低模式上相似(p = 0.75)。
在白内障合并严重青光眼患者中使用Phaco/MIGS在12个月内可显著降低IOP和药物负担,因此,在进行更具侵入性的青光眼手术之前,可作为患有明显白内障的严重青光眼患者的一个过渡治疗方法。cMIGS的联合作用可能会增强这种效果。